PTO-SB25 (07-09)
Approved for use through 07/31/2012. OMB 0851-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Parenvols Reduction Azt of 1995, no persons are required to respond to a collection from action unless it displays a valid OMB Common number.

TERMINAL DISC: AIMED TO ODMATE A DECURSIONAL POLICY TO PARENTMENT OF THE PROPERTY OF THE PROPERTY OF THE PARENTMENT OF THE P

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING	Docket Number (Optional)
REJECTION OVER A PENDING "REFERENCE" APPLICATION	022290.0159PTUS
In re Application of: Gauthier Pouliquen et al.	
Application No.: 10/580,023-Conf. #7549	
Filed: May 19, 2006	
For: PHARMACEUTICAL FORMULATIONS FOR THE PROLONGED RELEASE OF ACTIVE PRINCIPLE(S) AND THEIR APPLICATIONS	
The owner, Flamel Technologies percent letters in the instant application hereby disclains, except as provided below, the terminal part of the suturory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/580.035 (mid on March 28, 2007 March 28, 2007 as such term is defined in 3.5 U.S. C.15 and 1773, and as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforcable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application shall be, is successor or essigns.	
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date or the full statutory form as defined in SQ U.S. C. 154 and 175 of any patent granted on said reference application, "as the term of any patent granted on said reference application, and the service of the part of any patent of the parting reference application may be shortened by any terminal disclaimer filled prior to the grant of any patent or the perinding reference application," in the worth that any such patent: granted on the pending reference application, and the service of the patent of the patent granted on the pending reference application express for failure to pay a maintenance tell, is held unenthoroachle, is found invalid by a court of competent jurification, is elasticately declarimed in whole or terminally disclaimed under 3 CPR 1.3C, has all claims carried by a revarament or curificate, is referred by the patent of the patent of the full statutory term as whethered by any terminal declarimer field prior to its grant patent of the full statutory terms as whethered by any terminal declarimer field prior to its grant patent.	
Check either box 1 or 2 below, if appropriate.	
For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization.	
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that withful false statements and the like so made are punishable by fine or imprisonment, to both, under Scation 1001 of Tille 50 d he United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.	
The undersigned is an attorney or agent of record. Reg. No. 55,360	
/Matthew J. Laskoski/	May 6, 2011
Signature	Date
Matthew J. Laskoski	
Typed or printed name	
	(703) 744-8055
	Telephone Number
X Terminal disclaimer fee under 37 CFR 1.20(d) is included.	
WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
"Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.	